Evidence map›Paper›PMID 34684318›Full record

ReviewNutrients2021

Alcohol Use and the Risk of Communicable Diseases.

Neo K Morojele, Sheela V Shenoi, Paul A Shuper, Ronald Scott Braithwaite, Jürgen Rehm

Abstract readReview
In one paragraph

Review in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The influence of parents' history of alcohol use on their university-going children's drinking habits: A comparative study of students' drinking habits.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2025
    Article
  17. Article
  18. Article
  19. Therapeutic Potential ofJournal of microbiology and biotechnology · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Neo K MorojeleDepartment of Psychology, University of Johannesburg, Johannesburg 2006, South Africa.
Sheela V ShenoiSection of Infectious Diseases, Department of Medicine, Yale University School of Medicine, New Haven, CT 06510, USA.
Paul A ShuperCentre for Addiction and Mental Health, Institute for Mental Health Policy Research and Campbell Family Mental Health Research Institute, Toronto, ON M5S 2S1, Canada.
Ronald Scott BraithwaiteDivision of Comparative Effectiveness and Decision Science, Department of Population Health, NYU Grossman School of Medicine, New York University, New York, NY 10013, USA.
Jürgen RehmCentre for Addiction and Mental Health, Institute for Mental Health Policy Research and Campbell Family Mental Health Research Institute, Toronto, ON M5S 2S1, Canada.ORCID 0000-0001-5665-0385

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Could long-acting medications facilitate “ending AIDS by 2030” in southern Africa? An allocative efficiency analysisR01AA027481 · NIAAA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BRAITHWAITE, RONALD SCOTT · 2019 to 2023
$3.6M
Supplement to a microsimulation of alcohol control interventions to advance health equity and reverse the current decrease in life expectancy in the USR01AA028009 · NIAAA · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI PROBST, CHARLOTTE · 2020 to 2024
$2.4M
Enhancing HIV Pre-Exposure Prophylaxis (PrEP) by Targeting Hazardous Alcohol Use and Concurrent ConditionsUH3AA026212 · NIAAA · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI SHUPER, PAUL · 2019 to 2021
$740k
Enhancing HIV Pre-Exposure Prophylaxis (PrEP) by Targeting Hazardous Alcohol Use and Concurrent ConditionsUH2AA026212 · NIAAA · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI SHUPER, PAUL · 2017 to 2018
$293k
CIHR SMN-13950NCATS NIH HHS UL1 TR001863NIAAA NIH HHS 1R01AA028009-01A1NIAAA NIH HHS 5UH3AA026212-05NIAAA NIH HHS R01AA027481NIAAA NIH HHS R01 AA028009NIAAA NIH HHS UH2 AA026212NIAAA NIH HHS UH3 AA026212
6 · The paper itself

Abstract

The body of knowledge on alcohol use and communicable diseases has been growing in recent years. Using a narrative review approach, this paper discusses alcohol's role in the acquisition of and treatment outcomes from four different communicable diseases: these include three conditions included in comparative risk assessments to date-Human Immunodeficiency Virus (HIV)/AIDS, tuberculosis (TB), and lower respiratory infections/pneumonia-as well as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) because of its recent and rapid ascension as a global health concern. Alcohol-attributable TB, HIV, and pneumonia combined were responsible for approximately 360,000 deaths and 13 million disability-adjusted life years lost (DALYs) in 2016, with alcohol-attributable TB deaths and DALYs predominating. There is strong evidence that alcohol is associated with increased incidence of and poorer treatment outcomes from HIV, TB, and pneumonia, via both behavioral and biological mechanisms. Preliminary studies suggest that heavy drinkers and those with alcohol use disorders are at increased risk of COVID-19 infection and severe illness. Aside from HIV research, limited research exists that can guide interventions for addressing alcohol-attributable TB and pneumonia or COVID-19. Implementation of effective individual-level interventions and alcohol control policies as a means of reducing the burden of communicable diseases is recommended.

Indexed as

AlcoholismCommunicable DiseasesComorbidityCOVID-19Global Burden of DiseaseHIV InfectionsHumansRespiratory Tract InfectionsRiskSARS-CoV-2Tuberculosisalcoholcommunicable diseasesHIVinfectious diseasespneumoniasevere acute respiratory syndrome coronavirus 2tuberculosis

Identifiers

PMID34684318
PMCPMC8540096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.